Savara Future Growth
Future criteria checks 5/6
Savara is forecast to grow earnings and revenue by 54.2% and 66.4% per annum respectively while EPS is expected to grow by 54.5% per annum.
Key information
54.2%
Earnings growth rate
54.5%
EPS growth rate
| Biotechs earnings growth | 28.8% |
| Revenue growth rate | 66.4% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 03 Oct 2024 |
Recent future growth updates
Recent updates
Savara: Trial Successful, But I'm Only Half Convinced
Sep 09Savara: Today's Data 'Win' Rouses Market All Too Briefly
Jun 26Savara: The Binary Bet On Phase 3 Data
Jun 07Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?
Dec 14
Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Feb 16Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Oct 12Savara's rare lung disorder drug gets promising innovative medicine status in UK
Aug 26Savara GAAP EPS of -$0.06 in-line
Aug 11Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?
Jan 24Is Savara (NASDAQ:SVRA) A Risky Investment?
Jul 05Savara: They Failed Once, But They Are Trying Again
Jun 07The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares
Mar 17Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares
Feb 26Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex
Nov 24Savara EPS misses by $0.01
Nov 05Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 56 | -32 | -82 | N/A | 5 |
| 12/31/2025 | 2 | -86 | -86 | N/A | 7 |
| 12/31/2024 | N/A | -85 | -79 | N/A | 7 |
| 6/30/2024 | N/A | -75 | -72 | -72 | N/A |
| 3/31/2024 | N/A | -64 | -60 | -60 | N/A |
| 12/31/2023 | N/A | -55 | -51 | -51 | N/A |
| 9/30/2023 | N/A | -49 | -44 | -44 | N/A |
| 6/30/2023 | N/A | -43 | -39 | -39 | N/A |
| 3/31/2023 | N/A | -40 | -38 | -38 | N/A |
| 12/31/2022 | N/A | -38 | -35 | -35 | N/A |
| 9/30/2022 | N/A | -39 | -35 | -35 | N/A |
| 6/30/2022 | N/A | -39 | -36 | -36 | N/A |
| 3/31/2022 | N/A | -41 | -39 | -39 | N/A |
| 12/31/2021 | N/A | -43 | -40 | -40 | N/A |
| 9/30/2021 | 0 | -45 | -43 | -43 | N/A |
| 6/30/2021 | 0 | -46 | -41 | -41 | N/A |
| 3/31/2021 | 0 | -44 | -36 | -36 | N/A |
| 12/31/2020 | 0 | -50 | -43 | -40 | N/A |
| 9/30/2020 | 0 | -68 | -41 | -37 | N/A |
| 6/30/2020 | N/A | -69 | -45 | -42 | N/A |
| 3/31/2020 | N/A | -81 | -51 | -47 | N/A |
| 12/31/2019 | N/A | -78 | -45 | -45 | N/A |
| 9/30/2019 | N/A | -57 | -46 | -46 | N/A |
| 6/30/2019 | N/A | -57 | -43 | -43 | N/A |
| 3/31/2019 | N/A | -47 | -41 | -40 | N/A |
| 12/31/2018 | N/A | -62 | -39 | -39 | N/A |
| 9/30/2018 | N/A | -58 | -39 | -38 | N/A |
| 6/30/2018 | N/A | -52 | -38 | -38 | N/A |
| 3/31/2018 | N/A | -53 | N/A | -35 | N/A |
| 12/31/2017 | N/A | -31 | N/A | -28 | N/A |
| 9/30/2017 | 0 | -28 | N/A | -21 | N/A |
| 6/30/2017 | 0 | -25 | N/A | -16 | N/A |
| 3/31/2017 | 0 | -14 | N/A | -9 | N/A |
| 12/31/2016 | 0 | -11 | N/A | -8 | N/A |
| 12/31/2015 | 0 | -9 | N/A | -5 | N/A |
| 12/31/2014 | 2 | -6 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SVRA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Earnings vs Market: SVRA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SVRA is expected to become profitable in the next 3 years.
Revenue vs Market: SVRA's revenue (66.4% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: SVRA's revenue (66.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SVRA's Return on Equity is forecast to be high in 3 years time